Andrew J. Peacock
Golden Jubilee National Hospital
CardiologyPulmonary hypertensionPulmonary arteryDiabetes mellitusMedicine
What is this?
Publications 243
#1Joshua Hodgson (University of Cambridge)H-Index: 2
#2Emilia Swietlik (University of Cambridge)H-Index: 4
Last. Nicholas W. Morrell (University of Cambridge)H-Index: 66
view all 61 authors...
Objectives: Recently, rare heterozygous mutations in GDF2 were identified in patients with pulmonary arterial hypertension (PAH). GDF2 encodes the circulating bone morphogenetic protein, BMP9, whic...
#1Ekkehard Gruenig (University Hospital Heidelberg)H-Index: 39
#2Nicola Benjamin (University Hospital Heidelberg)H-Index: 8
Last. Andrew J. Peacock (Golden Jubilee National Hospital)H-Index: 45
view all 4 authors...
Multicentre trials on specialised exercise training and rehabilitation in patients with pulmonary hypertension are needed to provide further evidence on its haemodynamic effects and to show implementation in different healthcare systems is possible.
#1Luke Lawson McLean (Glas.: University of Glasgow)
#2Katherine Pellino (Golden Jubilee National Hospital)
Last. Alistair Colin Church (Glas.: University of Glasgow)
view all 6 authors...
Analysis of pulmonary arterial hypertension patients in Scotland across 20 years supports a recent French study suggesting there is no protective effect from obesity for this disease, in contrast to emerging evidence from the USA and China
#1Vallerie V. McLaughlin (UM: University of Michigan)H-Index: 44
#2Jean-Luc VachieryH-Index: 42
Last. Marius M. Hoeper (MHH: Hannover Medical School)H-Index: 79
view all 14 authors...
Abstract Background To compare patients with pulmonary arterial hypertension enrolled in the AMBITION trial with (excluded from the primary analysis set [ex-primary analysis set]) and without (primary analysis set) multiple risk factors for left ventricular diastolic dysfunction. Methods Treatment-naive patients with pulmonary arterial hypertension were randomised to once-daily ambrisentan and tadalafil combination therapy, ambrisentan monotherapy, or tadalafil monotherapy. The primary endpoint ...
#1David G. Kiely (University of Sheffield)H-Index: 36
#2David L. Levin (Mayo Clinic)H-Index: 21
Last. Andrew J. Swift (University of Sheffield)H-Index: 24
view all 27 authors...
Pulmonary hypertension (PH) is highly heterogeneous and despite treatment advances it remains a life-shortening condition. There have been significant advances in imaging technologies, but despite ...
#1Martin Johnson (Golden Jubilee National Hospital)H-Index: 15
#2Andrew J. Peacock (Golden Jubilee National Hospital)H-Index: 45
Exercise training as treatment has become well established in many cardiorespiratory conditions. This is also increasingly the case in pulmonary arterial hypertension, where several studies have de...
1 CitationsSource
#1Eleni Sofianopoulou (University of Cambridge)H-Index: 5
#2Stephen Kaptoge (University of Cambridge)H-Index: 51
Last. Nicholas W. Morrell (University of Cambridge)H-Index: 66
view all 33 authors...
While traffic and air pollution exposure is associated with increased mortality in numerous diseases, its association with disease severity and outcomes in pulmonary arterial hypertension (PAH) remains unknown. Exposure to particulate matter with a 50% cut-off aerodynamic diameter ≤2.5 μm (PM2.5), nitrogen dioxide (NO2) and indirect measures of traffic-related air pollution (distance to main road and length of roads within buffer zones surrounding residential addresses) were estimated for 301 pa...
2 CitationsSource
#1Christopher J. Rhodes (Imperial College London)H-Index: 79
#2Ken Batai (UA: University of Arizona)H-Index: 9
Last. Martin R. Wilkins (Imperial College London)H-Index: 45
view all 118 authors...
Summary Background Rare genetic variants cause pulmonary arterial hypertension, but the contribution of common genetic variation to disease risk and natural history is poorly characterised. We tested for genome-wide association for pulmonary arterial hypertension in large international cohorts and assessed the contribution of associated regions to outcomes. Methods We did two separate genome-wide association studies (GWAS) and a meta-analysis of pulmonary arterial hypertension. These GWAS used d...
6 CitationsSource
#1Ekkehard Grünig (University Hospital Heidelberg)H-Index: 25
#2Christina A. Eichstaedt (University Hospital Heidelberg)H-Index: 11
Last. Andrew J. Peacock (Golden Jubilee National Hospital)H-Index: 45
view all 36 authors...
Objectives of this European Respiratory Society task force were to summarise current studies, to develop strategies for future research and to increase availability and awareness of exercise training for pulmonary hypertension (PH) patients. An evidence-based approach with clinical expertise of the task force members, based on both literature search and face-to-face meetings was conducted. The statement summarises current knowledge and open questions regarding clinical effects of exercise traini...
1 CitationsSource
#1Jean-Luc VachieryH-Index: 42
#2Nazzareno Galiè (UNIBO: University of Bologna)H-Index: 80
Last. Lewis J. Rubin (UCSD: University of California, San Diego)H-Index: 97
view all 13 authors...
BACKGROUND In the randomized, double-blind, event-driven AMBITION study, initial combination therapy with ambrisentan and tadalafil was associated with a 50% reduction in risk of clinical failure (first occurrence of all-cause death, hospitalization for worsening pulmonary arterial hypertension [PAH], disease progression, or unsatisfactory long-term clinical response) vs pooled monotherapy. These results were primarily driven by a reduction in PAH-related hospitalization in the combination thera...